ChromaDex Corp announced an exclusive worldwide patent license and research agreement with The Scripps Research Institute (TSRI) to identify the potential role of Niagen in treating breast cancer.
ChromaDex said it signed the new patent license and research agreement “gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie Felding.”
ChromaDex said: “Dr. Felding’s patented discoveries include the enhancement of NAD+ metabolism through treatment with NAD+ precursors to potentiate the effects of endocrine therapy in breast cancer, inhibit resistance of breast cancer cells to endocrine therapy, and re-instate sensitivity in breast cancer cells that are unresponsive to endocrine treatments such as Tamoxifen.
“The research agreement will build upon the previous material transfer agreement, and if successful, will yield the data and tools required for the development of a clinical trial evaluating a novel combination therapy consisting of nicotinamide riboside (NR) and endocrine therapy in the treatment of breast cancer.”
ChromaDex CEO Frank Jaksch said: “TSRI was one of the first institutions we signed a material transfer agreement with on NR back in 2013.
“It’s great to see that TSRI’s discoveries have now sparked a collaborative partnership that could lead to another drug application.”
ChromaDex scientific affairs director Amy Boileau said: “Though the research is still early stage, the findings by Dr. Felding and her team are remarkable.
“We are thrilled to expand our partnership with TSRI and continue advancing research that holds great promise for improved treatment of breast cancer.”